AUTL Autolus Therapeutics plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1730463 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY168.8%
TTM net income YoY-13.9%
TTM EPS YoY-15.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin35.8%
Operating margin-159.6%
Net margin-186.4%
FCF margin-131.1%
EBITDA margin-153.1%
Returns
ROE-174.9%
ROA-43.2%
ROIC (approx.)—
Asset turnover0.23x
Leverage & solvency
Liabilities / assets94.8%
Debt / equity0.00x
Current ratio3.72x
Interest coverage-4.79x
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $75.39M | $10.12M |
| Cost of revenue | $96.37M | $11.39M |
| Gross profit | -$20.98M | -$1.27M |
| R&D expense | $117.69M | $138.44M |
| SG&A expense | $131.87M | $101.72M |
| Operating income | -$270.54M | -$241.43M |
| Interest expense | $36.67M | $9.29M |
| Pretax income | -$285.56M | -$219.13M |
| Income tax | $1.97M | $1.53M |
| Net income | -$287.53M | -$220.66M |
| EBITDA | -$262.25M | -$233.87M |
| EPS (basic) | -1.08 | -0.86 |
| EPS (diluted) | -1.08 | -0.86 |
| Weighted avg. shares (diluted) | 266.14M | 255.16M |
| Balance sheet | ||
| Cash & equivalents | $104.13M | $228.80M |
| Short-term investments | $196.58M | $360.64M |
| Receivables | $24.02M | $15,000 |
| Inventory | $33.21M | $4.14M |
| Current assets | $435.92M | $660.93M |
| PP&E, net | $63.56M | $49.55M |
| Intangibles | $19.81M | $12.37M |
| Total assets | $589.07M | $782.73M |
| Current liabilities | $73.44M | $60.74M |
| Total liabilities | $410.94M | $355.40M |
| Shareholders' equity | $178.13M | $427.32M |
| Cash flow statement | ||
| Operating cash flow | -$283.57M | -$206.27M |
| Capital expenditure | $19.04M | $22.07M |
| Free cash flow | -$302.61M | -$228.35M |
| Investing cash flow | $158.46M | -$394.55M |
| Financing cash flow | -$4.34M | $589.55M |
| Depreciation & amortization | $8.30M | $7.55M |
| Stock-based compensation | $14.44M | $15.47M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.